Development of molecular sterility assay for rapid quality release of cord blood erythrocytes units for transfusion
Transfusion · 2025
DOI: 10.1111/trf.18084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Laia Closa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Histocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain. Hauptthemen laut MEDLINE: Fetal Blood, Erythrocytes, Erythrocyte Transfusion, Blood Preservation. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Background
Umbilical cord blood (CB) units stored in banks are an important source of hematopoietic stem cells for transplantation and other cell therapies. New applications, such as their use in transfusions, require rapid quality release as cord blood red blood cells (CB‐RBC) have a shorter shelf life. Study Design and Methods This project aims to investigate the most prevalent microbial contaminants in CB preparations and validate a rapid sterility testing strategy for CB‐RBC based on an automated system (BACT/ALERT®) in tandem with a molecular assay (real‐time PCR) capable of detecting at least 100 CFU/mL of Cutibacterium acnes in CB‐RBC to accelerate the detection of the most common slow‐growing bacteria.
Results
Microbial contamination incidence was assessed by reviewing 4696 CB sterility tests, revealing a positivity rate of 3.4%, with C. acnes being the most common slow‐growing pathogen. The BACT/ALERT® system, which was validated according to European Pharmacopeia guidelines, was an appropriate method for sterility testing of CB‐RBC, although it required up to 14 days of culture to detect C. acnes when iFAPlus and iFNPlus bottles were used to neutralize antimicrobials. Interestingly, the BACT/ALERT® method detected C. acnes at 30 CFU/mL within 14 days, while real‐time PCR identified concentrations ≥65 CFU/mL by Day 4.
Discussion
In conclusion, we developed a rapid sterility testing strategy that combines automated culture systems and real‐time PCR for early microbial contamination, enhancing CB‐RBC shelf life for transfusion and emphasizing the importance of combining detection methods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Histocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
- Transfusional Medicine Group, Vall d'Hebron Research Institute-Autonomous University of Barcelona (VHIR-UAB), Barcelona, Spain.
- Cell and Advanced Therapy Service, Blood and Tissue Bank, Barcelona, Spain.
- Congenital Coagulopathy Laboratory, Blood and Tissue Bank, Barcelona, Spain.
- Cell Laboratory, Blood and Tissue Bank, Barcelona, Spain.
- CIBER of Cardiovascular Diseases, Madrid, Spain.
ORCID-Profile: Laia Closa, Dinara Samarkanova
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Closa, L., Samarkanova, D., Lera, C., Gonzalez, N., Lloret, M., Codinach, M., Aran, G., Fernandez-Sojo, J., Vidal, F., Soria, M. G., & Querol, S. (2025). Development of molecular sterility assay for rapid quality release of cord blood erythrocytes units for transfusion. Transfusion. https://doi.org/10.1111/trf.18084
Vancouver
Closa L, Samarkanova D, Lera C, Gonzalez N, Lloret M, Codinach M, et al. Development of molecular sterility assay for rapid quality release of cord blood erythrocytes units for transfusion. Transfusion. 2025. doi:10.1111/trf.18084
BibTeX
@article{Closa2025,
author = {Closa, Laia and Samarkanova, Dinara and Lera, Carina and Gonzalez, Noemí and Lloret, Mireia and Codinach, Margarita and Aran, Gemma and Fernandez-Sojo, Jesús and Vidal, Francisco and Soria, Maria Gloria and Querol, Sergi},
title = {Development of molecular sterility assay for rapid quality release of cord blood erythrocytes units for transfusion},
journal = {Transfusion},
year = {2025},
doi = {10.1111/trf.18084}
}
EUVIMED